D. E. Shaw & Co., Inc. Aadi Bioscience, Inc. Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.46 - $2.31 $34,006 - $53,804	-23,292 Reduced 56.69%	17,796 $25,000
Q1 2024 May 15, 2024	BUY	$1.59 - $2.44 $27,355 - $41,980	17,205 Added 72.04%	41,088 $96,000
Q4 2023 Feb 14, 2024	BUY	$1.97 - $5.41 $10,703 - $29,392	5,433 Added 29.45%	23,883 $48,000
Q3 2023 Nov 14, 2023	BUY	$4.84 - $7.13 $89,298 - $131,548	18,450 New	18,450 $89,000
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $131,840 - $204,198	11,395 New	11,395 $140,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $78.4M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.